Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 17 studies | 47% ± 12% | |
natural killer cell | 6 studies | 23% ± 7% | |
CD16-positive, CD56-dim natural killer cell, human | 5 studies | 23% ± 7% | |
microglial cell | 5 studies | 24% ± 6% | |
epithelial cell | 5 studies | 24% ± 13% | |
Mueller cell | 5 studies | 44% ± 13% | |
oligodendrocyte precursor cell | 4 studies | 31% ± 8% | |
GABAergic neuron | 3 studies | 30% ± 9% | |
glutamatergic neuron | 3 studies | 39% ± 14% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 28% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 100% | 2112.78 | 1808 / 1809 | 100% | 37.56 | 472 / 472 |
breast | 100% | 1967.37 | 459 / 459 | 100% | 19.92 | 1116 / 1118 |
kidney | 100% | 1223.64 | 89 / 89 | 100% | 44.83 | 899 / 901 |
lung | 100% | 1893.48 | 577 / 578 | 100% | 18.36 | 1154 / 1155 |
prostate | 100% | 1500.43 | 245 / 245 | 100% | 13.75 | 500 / 502 |
thymus | 100% | 1604.38 | 653 / 653 | 100% | 22.61 | 602 / 605 |
ovary | 100% | 1616.34 | 180 / 180 | 99% | 13.00 | 427 / 430 |
esophagus | 100% | 1617.41 | 1445 / 1445 | 99% | 15.69 | 181 / 183 |
uterus | 100% | 2480.81 | 170 / 170 | 99% | 16.78 | 453 / 459 |
stomach | 99% | 1063.01 | 355 / 359 | 100% | 14.87 | 285 / 286 |
brain | 98% | 1190.75 | 2598 / 2642 | 100% | 20.08 | 705 / 705 |
intestine | 100% | 1590.56 | 966 / 966 | 98% | 15.02 | 517 / 527 |
bladder | 100% | 1655.24 | 21 / 21 | 98% | 15.44 | 494 / 504 |
adrenal gland | 100% | 1027.52 | 257 / 258 | 97% | 12.98 | 224 / 230 |
liver | 100% | 1512.75 | 226 / 226 | 97% | 13.95 | 392 / 406 |
pancreas | 98% | 899.95 | 320 / 328 | 97% | 19.54 | 172 / 178 |
adipose | 100% | 1994.55 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2614.93 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 36.95 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 39.23 | 29 / 29 |
muscle | 100% | 3667.53 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2356.64 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 16.22 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.59 | 1 / 1 |
peripheral blood | 100% | 6340.87 | 928 / 929 | 0% | 0 | 0 / 0 |
heart | 95% | 1061.52 | 819 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0015835 | Biological process | peptidoglycan transport |
GO_0045087 | Biological process | innate immune response |
GO_0006811 | Biological process | monoatomic ion transport |
GO_0033023 | Biological process | mast cell homeostasis |
GO_0034157 | Biological process | positive regulation of toll-like receptor 7 signaling pathway |
GO_0045089 | Biological process | positive regulation of innate immune response |
GO_0089708 | Biological process | L-histidine transmembrane export from vacuole |
GO_0034165 | Biological process | positive regulation of toll-like receptor 9 signaling pathway |
GO_0070434 | Biological process | positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway |
GO_0015833 | Biological process | peptide transport |
GO_0070424 | Biological process | regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway |
GO_0070430 | Biological process | positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway |
GO_0015031 | Biological process | protein transport |
GO_0140206 | Biological process | dipeptide import across plasma membrane |
GO_0015817 | Biological process | histidine transport |
GO_0048302 | Biological process | regulation of isotype switching to IgG isotypes |
GO_1902600 | Biological process | proton transmembrane transport |
GO_0034161 | Biological process | positive regulation of toll-like receptor 8 signaling pathway |
GO_0035579 | Cellular component | specific granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0036020 | Cellular component | endolysosome membrane |
GO_0071916 | Molecular function | dipeptide transmembrane transporter activity |
GO_0005290 | Molecular function | L-histidine transmembrane transporter activity |
GO_0015333 | Molecular function | peptide:proton symporter activity |
GO_0015647 | Molecular function | peptidoglycan transmembrane transporter activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SLC15A4 |
Protein name | Solute carrier family 15 member 4 Solute carrier family 15 member 4 (Peptide transporter 4) (Peptide/histidine transporter 1) (hPHT1) |
Synonyms | PTR4 PHT1 FP12591 |
Description | FUNCTION: Proton-coupled amino-acid transporter that mediates the transmembrane transport of L-histidine and some di- and tripeptides from inside the lysosome to the cytosol, and plays a key role in innate immune response . Able to transport a variety of di- and tripeptides, including carnosine and some peptidoglycans . Transporter activity is pH-dependent and maximized in the acidic lysosomal environment (By similarity). Involved in the detection of microbial pathogens by toll-like receptors (TLRs) and NOD-like receptors (NLRs), probably by mediating transport of bacterial peptidoglycans across the endolysosomal membrane: catalyzes the transport of certain bacterial peptidoglycans, such as muramyl dipeptide (MDP), the NOD2 ligand, and L-alanyl-gamma-D-glutamyl-meso-2,6-diaminoheptanedioate (tri-DAP), the NOD1 ligand . Required for TLR7, TLR8 and TLR9-mediated type I interferon (IFN-I) productions in plasmacytoid dendritic cells (pDCs) . Independently of its transporter activity, also promotes the recruitment of innate immune adapter TASL to endolysosome downstream of TLR7, TLR8 and TLR9: TASL recruitment leads to the specific recruitment and activation of IRF5 . Required for isotype class switch recombination to IgG2c isotype in response to TLR9 stimulation (By similarity). Required for mast cell secretory-granule homeostasis by limiting mast cell functions and inflammatory responses (By similarity). . |
Accessions | ENST00000376744.8 ENST00000376740.8 Q8N697 B6ZDF2 H7BYB7 ENST00000266771.10 [Q8N697-1] |